LentiBOOST® can be applied to a wide range of clinically relevant cell types, including CD34+ hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), neuronal stem cells, primary T cells, hard-to-transduce murine T cells, NK cells, and fibroblasts. It is ideal for clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.
LentiBOOST offers many benefits for drug development, including increased and titratable vector copy number per cell and increased safety in line with FDA/EMA criteria.
Its successful track record includes integration into more than 20 Phase I/II and III clinical trials in the US and Europe as well as manufacturing of an approved product.